Drugs / tgAAG76
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00643747 | Jan 2007 → Dec 2014 | retinal degeneration | University College, London | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tgAAG76 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00643747 ↗ |
| Action | Restore | “recombinant adeno-associated virus vector 2/2 expressing RPE65 complementary DNA (cDNA)” PMID 18441371 ↗ Apr 2008 |
| Modality | Gene therapy (AAV / viral vector) | “administered to three young adult patients subretinal injections of recombinant adeno-associated virus vector 2/2 expressing RPE65 complementary DNA (cDNA)” PMID 18441371 ↗ Apr 2008 |
| Route | Other | “subretinal injections of recombinant adeno-associated virus vector 2/2 expressing RPE65 complementary DNA (cDNA)” PMID 18441371 ↗ Apr 2008 |
| Target | RPE65 | “subretinal delivery of a recombinant adeno-associated viral vector carrying RPE65” PMID 26605849 ↗ 2015 |